Phase 3
Completed N=112
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Atrial Fibrillation · Cardioversion · Cerebrovascular Stroke
Source: ClinicalTrials.gov NCT01924065 ↗
Enrolled (actual)
112
Serious AEs
17.0%
Results posted
Oct 2024
Primary outcomePrimary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between 2.0-3.0. Those who do not want to use warfarin will be given an approved new oral anticoagulant agent instead of warfarin for 3 weeks.
If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be performed. Other patients in the both groups will undergo electrical cardioversion. After the procedures all the patients will be given oral anticoagulant for at least 4 Weeks. All patients will have neurological examination and diffusion magnetic resonance imaging (MRI) at baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic events detected by diffusion MRI will be recorded. Any bleeding events will also be recorded.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli |
9; 11 | — |
| PRIMARY Efficacy Clinical End-point |
7; 9 | — |
| PRIMARY Ischemic Stroke/Transient Ischemic Attack |
7; 4 | — |
| PRIMARY Acute Ischemia in MRI |
2; 4 | — |
| PRIMARY Mortality |
3; 2 | — |
| PRIMARY Hemorrhagic Stroke |
1; 2 | — |
| PRIMARY Gastrointestinal Bleeding |
3; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with the age of more than 18 years who are planned to undergo electrical or medical cardioversion
Exclusion Criteria
- Urgent cardioversion
- Patients who have implanted pace-makers or other metal devices
- Claustrophobia
- Hematological disorders disabling patients to receive anticoagulant agents
- Atrial fibrillation secondary to temporary causes.
- Serious rheumatic heart valve disease
- Hyperthyroidism
- History of malignancy
- Left atrium diameter > 55 mm
- Ejection fraction < 0.25
Data sourced from ClinicalTrials.gov (NCT01924065). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.